CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes
- PMID: 10607752
- DOI: 10.1093/intimm/12.1.73
CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes
Abstract
Human CD137 is a member of the tumor necrosis factor (TNF) receptor family and the homologue of murine 4-1BB. Recent studies have demonstrated that CD137 promotes accessory T cell activation, and regulates proliferation and survival of T lymphocytes. This study reports on the expression and function of CD137 in peripheral blood monocytes. While monocytes showed constitutive expression in 10 out of 18 healthy donors, CD137 was not expressed on resting T or B lymphocytes. Immobilized antibodies to CD137 markedly induced the production of IL-8 and TNF-alpha protein and mRNA, and led to inhibition of IL-10 expression by primary monocytes. Furthermore, cross-linking of CD137 on monocytes resulted in an increase of B lymphocyte apoptosis mediated by direct cell-cell contact of both cell populations. In conclusion, this study identified CD137 as a new receptor involved in monocyte activation by inducing a characteristic cytokine release profile. In addition, CD137 may play a role in monocyte-dependent control of B lymphocyte survival.
Similar articles
-
CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling.J Immunol. 1998 Mar 1;160(5):2488-94. J Immunol. 1998. PMID: 9498794
-
Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation.Biochem Biophys Res Commun. 2000 Jun 24;273(1):117-22. doi: 10.1006/bbrc.2000.2889. Biochem Biophys Res Commun. 2000. PMID: 10873573
-
CD137-induced apoptosis is independent of CD95.Immunology. 1999 Sep;98(1):42-6. doi: 10.1046/j.1365-2567.1999.00851.x. Immunology. 1999. PMID: 10469232 Free PMC article.
-
Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.Immunol Res. 2004;29(1-3):197-208. doi: 10.1385/IR:29:1-3:197. Immunol Res. 2004. PMID: 15181282 Review.
-
The therapeutic potential of 4-1BB (CD137) in cancer.Curr Cancer Drug Targets. 2005 Aug;5(5):357-63. doi: 10.2174/1568009054629681. Curr Cancer Drug Targets. 2005. PMID: 16101383 Review.
Cited by
-
Positive and negative functions of B lymphocytes in tumors.Oncotarget. 2016 Aug 23;7(34):55828-55839. doi: 10.18632/oncotarget.10094. Oncotarget. 2016. PMID: 27331871 Free PMC article. Review.
-
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.J Clin Invest. 2002 Mar;109(5):651-9. doi: 10.1172/JCI14184. J Clin Invest. 2002. PMID: 11877473 Free PMC article.
-
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.Nat Commun. 2019 May 20;10(1):2141. doi: 10.1038/s41467-019-10088-1. Nat Commun. 2019. PMID: 31105267 Free PMC article.
-
4-1BB signaling beyond T cells.Cell Mol Immunol. 2011 Jul;8(4):281-4. doi: 10.1038/cmi.2010.82. Epub 2011 Jan 10. Cell Mol Immunol. 2011. PMID: 21217771 Free PMC article. Review.
-
Therapeutic vaccination with tumor cells that engage CD137.J Mol Med (Berl). 2003 Feb;81(2):71-86. doi: 10.1007/s00109-002-0413-8. Epub 2003 Feb 8. J Mol Med (Berl). 2003. PMID: 12601523 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials